Hematology
Mostrando 1-12 de 295 artigos, teses e dissertações.
-
1. É necessário encaminhar pacientes com traço falciforme ao hematologista?
Não é necessário encaminhar pacientes com traço falciforme ao hematologista.
Portadores de traço falciforme não possuem uma doença, mas uma característica genética que não requer tratamento.
Esse achado é detectado pela eletroforese de hemoglobina ou pelo Teste do Pezinho que identifica mutação de um alelo do gene da hemoglobina,
Núcleo de Telessaúde Rio Grande do Sul. Publicado em: 12/06/2023
-
2. Como investigar um resultado de ferritina elevado?
Os casos de hiperferritinemia devem ser inicialmente investigados repetindo-se a dosagem de ferritina, além da dosagem de saturação de transferrina e hemograma com plaquetas. Deve-se investigar se o paciente tem história familiar de sobrecarga de ferro ou cirrose, história de reposição de ferro em excesso ou sobrecarga secundária a transfusões, u
Núcleo de Telessaúde Rio Grande do Sul. Publicado em: 12/06/2023
-
3. Quais as causas de aumento da ferritina sérica?
A ferritina sérica elevada é encontrada em um grande espectro de condições, tanto genéticas como adquiridas 3. Pode estar elevada em condições como hepatopatias, alcoolismo, malignidades, doenças infecciosas e inflamatórias (ex artrite reumatoide), hipertireoidismo, infarto agudo do miocárdio, doença renal avançada e sobrecarga de ferro (hemos
Núcleo de Telessaúde Espírito Santo. Publicado em: 12/06/2023
-
4. Quais são as causas e qual é a investigação inicial de plaquetopenia assintomática?
Plaquetopenia é um achado frequente no hemograma, e nem sempre significa presença de alguma doença. Sempre que não houver uma causa conhecida, e as plaquetas estiverem acima de 50.000 células/mm³, deve-se inicialmente confirmar se a plaquetopenia é real repetindo o exame, para excluir erro laboratorial ou agregação in vitro. Alguns indivíduos t�
Núcleo de Telessaúde Rio Grande do Sul. Publicado em: 12/06/2023
-
5. Improving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USA
ABSTRACT Introduction: Although several combination therapies for acute myeloid leukemia (AML) have emerged recently, there has been a lack of published surveys and educational projects focused on these important treatment options. We aimed to improve the oncology team members’ knowledge and awareness of several FDA approved combination therapies for AML,
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
6. Early integration of palliative care in hematology: an urgency for patients, a challenge for physicians
ABSTRACT Introduction: Early integration between palliative care and other medical specialties in the care of patients with serious illnesses is consolidating itself as good medical practice, based on scientific and ethical evidence. Despite this, palliative care is still not part of the routine care of patients with hematological diseases, even in speciali
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
7. Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature
Abstract Introduction Coronavirus disease 2019 (COVID-19) may present with extrapulmonary manifestations, including hematologic changes. Previous studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) can interact with the renin-angiotensin system, ultimately causing increased production of angiotensin II. By reporting the cases o
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
8. Radiological patterns of pulmonary fungal infection in pediatric hematology and oncology patients
Resumo Objetivo: O objetivo deste estudo é descrever os achados radiológicos de infecções fúngicas invasivas em crianças com doenças onco-hematológicas em um único centro, de acordo com a classificação antiga e a atual de imagens típicas e atípicas. Materiais e Métodos: Foram revisados os prontuários de todos os pacientes com infecção fún
Radiologia Brasileira. Publicado em: 2022
-
9. Comparative analysis of hematological parameters of first-time and repeat blood donors: Experience of a blood bank in southern Nigeria
ABSTRACT Introduction: The safety of a blood transfusion practice is anchored on safe blood from a healthy donor, while further protecting the donor from future harm. This study aimed to evaluate the hematological parameters of blood donors in view of their donor category to aid in assessing the safety threshold in terms of donation frequency. Methods: Thi
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
10. Impact of quality of response on survival outcomes among multiple myeloma patients treated with novel agents – a retrospective analysis
Abstract BACKGROUND: In this era of target therapies, novel data on the correlation between response endpoints and survival outcomes in multiple myeloma have arisen. OBJECTIVE: To determine the impact of quality of response on clinical outcomes, using first-line treatment, and identify risk factors influencing progression-free survival (PFS) and overall su
Sao Paulo Medical Journal. Publicado em: 2022
-
11. The relationship between red cell distribution width and prognostic scores in myelodysplastic syndrome
ABSTRACT Introduction: The myelodysplastic syndrome (MDS) represents a group of hematopoietic neoplasms that is characterized by clonal hematopoiesis, cytopenia and abnormal cellular maturation. Red cell distribution width (RDW) refers to the variation degree of erythrocyte size and it is a reflection of anisocytosis. Higher values have been linked to adver
Hematology, Transfusion and Cell Therapy. Publicado em: 2022
-
12. Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
ABSTRACT This manuscript summarizes the results of the consensus meeting composed of hematologists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and fr
Hematol., Transfus. Cell Ther.. Publicado em: 2021-06